Azilsartan (EDARBI): A New Angiotensin Receptor Blocker (ARB) for Hypertension

Approved by the FDA for Marketing in the USA

Randa Hilal-Dandan


AccessMedicine from McGraw-Hill 

In This Article

Special Populations

Symptomatic hypotension may occur in volume- and/or salt-depleted patients (e.g., patients using diuretics) and extra care should be exercised in these patients until blood pressure is stabilized.[2] Like other ARBs, caution also should be used in patients whose arterial blood pressure or renal function are dependent on the renin-angiotensin system (e.g., renal artery stenosis) as it may cause hypotension, oliguria, azotemia and renal failure. No dose adjustments are necessary for elderly patients or patients with renal impairment or mild to moderate hepatic impairment.

Like other ARBs, azilsartan should be discontinued during pregnancy (Category C and D). It is not known whether azilsartan is excreted in breast milk; nursing mothers should either discontinue the drug or discontinue nursing.[2]